These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30913454)

  • 21. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.
    Shinmei S; Sentani K; Hayashi T; Sakamoto N; Goto K; Oo HZ; Naito Y; Teishima J; Matsubara A; Oue N; Kuniyasu H; Yasui W
    Urol Oncol; 2014 Aug; 32(6):769-78. PubMed ID: 24968948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Updated treatments of castration-resistant prostate cancer].
    Wei YF; Gu XJ; Zhu QY
    Zhonghua Nan Ke Xue; 2016 May; 22(5):455-61. PubMed ID: 27416673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
    Batra A; Winquist E
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):271-282. PubMed ID: 30422005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New progress of castration-resistant prostate cancer immunotherapy].
    Liu JP; Wang H
    Zhonghua Wai Ke Za Zhi; 2016 Oct; 54(10):787-791. PubMed ID: 27686644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards precision oncology in advanced prostate cancer.
    Ku SY; Gleave ME; Beltran H
    Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
    Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
    Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
    Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D
    Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging treatment options for patients with castration-resistant prostate cancer.
    George D; Moul JW
    Prostate; 2012 Feb; 72(3):338-49. PubMed ID: 21748753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
    Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug discovery in advanced prostate cancer: translating biology into therapy.
    Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS
    Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    Virgo KS; Basch E; Loblaw DA; Oliver TK; Rumble RB; Carducci MA; Nordquist L; Taplin ME; Winquist E; Singer EA
    J Clin Oncol; 2017 Jun; 35(17):1952-1964. PubMed ID: 28441112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision medicine for advanced prostate cancer.
    Mullane SA; Van Allen EM
    Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
    Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
    Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.